Skip to content

Comparison of the effect of Hibiscus sabdariffa L. extract and thiazide on treatment of hypertension in patients with mild chronic kidney disease : A randomized controlled clinical trial: double blinded

Comparison of the effect of Hibiscus sabdariffa L. extract and thiazide on treatment of hypertension in patients with mild chronic kidney disease

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210926052600N1
Enrollment
64
Registered
2021-12-22
Start date
2021-03-21
Completion date
Unknown
Last updated
2022-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with hypertension with mild renal failer. Hypertensive chronic kidney disease

Interventions

Intervention 1: In the first group, 25 mg of hydrochlorothiazide tablets and 40 mg of valsartan tablets daily every 12 hours for 3 months. Intervention 2: Control group: Control group: Group 2: 420 mg

Sponsors

Gorgan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Non-pregnant man or woman 18 to 70 years old 2. Consent to participate in the study 3. A patient with confirmed clinical signs of hypertension with mild renal failure 4. Abnormal blood pressure (=> 130/80 according to AHA criteria) 5. Patient follow-up

Exclusion criteria

Exclusion criteria: 1- Allergy to the plant 2- Normal blood pressure (mm HgSBP = 120; DBP = 80 mm Hg) / blood pressure below 100 and blood pressure => 160/100 3- Patients with diabetes mellitus, severe renal failure, coronary artery disease, heart failure, malignant hypertension [BP = 180/110], etc.) 4- Study of changing antihypertensive drugs in patients 5- Systolic blood pressure below 100 during the study 6- Pregnancy 7. Any metabolic or malabsorption disease that may interfere with the absorption of hibiscus (such as celiac disease, chronic pancreatitis, etc.). 8- Use of psychiatric drugs (mood stabilizer, anti-depressant, anti-anxiety or anti-psychotic

Design outcomes

Primary

MeasureTime frame
Patients' blood pressure changes,, albuminuria and proteinuria. Timepoint: Blood pressure at the beginning and 3 months after the intervention. Method of measurement: Based on laboratory Examination.;Electrolytes. Timepoint: Electrolytes at the beginning and 3 months after the start of the intervention. Method of measurement: Based on laboratory Examination.;Albuminuria and proteinuria. Timepoint: albuminuria, proteinuria, GFR according to MDRD formula. Method of measurement: Based on laboratory Examination.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehdad Dehkhoda

Gorgan University of Medical Sciences

forwar.b1367@gmail.com+98 17 3220 2154

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026